临床研究
Copyright ©The Author(s) 2011.
世界华人消化杂志. 2011-03-08; 19(7): 700-704
在线出版 2011-03-08. doi: 10.11569/wcjd.v19.i7.700
表1 16例进展期结直肠癌患者(术前、术后)血清CXCL8与健康人差别比较 (曼-怀特尼秩检验)
平均秩(μg/L)秩次和(μg/L)曼-惠特尼U值威尔科森(W值)Z值近似概率(2-tailed)精确概率[2×(1-tailed Sig.)]
术前CXCL8
健康人(n = 10)4.4022.07.022.0-2.7250.0060.004
患者(n = 16)13.06209.0
术后CXCL8
健康人(n = 10)7.7038.5023.538.5-1.3630.1730.179
患者(n = 16)12.03192.50
表2 16例结直肠癌患者术前、术后血清CXCL8水平差别比较 (配对符号秩检验, n = 16)
mean±SD(μg/L)最小值(μg/L)最大值(μg/L)百分位数
Z值近似概率(2-tailed)
25th50th(中位数)75th
CXCL8
术前69.44±82.1410.10332.717.0840.46106.433.310.001
术后23.68±20.676.5077.410.9615.3532.66
表3 16例不同临床病理学特征的进展期结直肠癌患者血清CXCL8(术前/术后)差别比较
病理学特征n平均秩(μg/L)秩次和(μg/L)曼-惠特尼(U)威尔科森(W值)Z值近似概率(2-tailed)精确概率 [2×(1-tailed Sig.)]
性别8.0/22.536.0/50.5-2.488/-0.9530.013/0.340.012/0.351
75.14/7.2136.0/50.5
911.11/9.50100.0/85.5
年龄28.00/15.564.0/39.5-0.42/-1.7340.674/0.080.72/0.08
<6589.0/6.4472.0/51.50
≥6588.0/10.5664.0/84.50
肿瘤大小(cm)5.0/11.533.0/39.5-2.805/-2.1190.005/0.0340.003/0.031
≤5.074.71/5.6433.0/39.5
>5.0911.44/10.72103.0/96.5
肿瘤部位11.0/24.577.0/90.5-1.869/-0.340.062/0.7340.069/0.743
右侧511.8/9.159.0/45.5
左侧117.0/8.2377.0/90.5
T分期6.0/7.512.0/13.5-1.816/-1.6160.069/0.1060.082/0.111
T234.0/4.512.0/13.5
T3-4139.54/9.42124.0/122.5
N分期16.0/25.544.0/53.5-1.641/-0.6360.101/0.5250.114/0.536
N076.29/7.6444.0/53.5
N1-2910.22/9.1792.0/82.5
分化23.0/21.589.0/87.5-0.51/-0.680.61/0.4960.661/0.51
高/中分化118.09/7.9589.0/87.5
低分化59.40/9.747.0/48.5
表4 16例进展期结直肠癌患者术前血清CXCL8与临床病理学因素相关性分析 (两相关样本非参数检验)
术前CXCL8T分期N分期分化血小板数量术前CEA术前CA19-9
术前CXCL8相关系数1.0000.1800.1800.1100.2200.2600.080
概率(2-tailed)0.4000.4000.5900.3500.1800.650
T分期相关系数0.1801.0000.6200.2200.2700.1700.180
概率(2-tailed)0.4000.0100.3400.3000.4200.400
N分期相关系数0.1800.6201.0000.2100.2400.1000.110
概率(2-tailed)0.4000.0100.3600.3500.6600.580
分化相关系数0.1100.2200.2101.0000.2200.7000.451
概率(2-tailed)0.5900.3400.3600.4000.0010.029
血小板数量相关系数0.2200.2700.2400.2201.000-0.020-0.110
概率(2-tailed)0.3500.3000.3500.4000.9300.640
术前CEA相关系数0.2600.1700.1000.700-0.0201.0000.580
概率(2-tailed)0.1800.4200.6600.0010.9300.003
术前CA19-9相关系数0.0800.1800.1100.451-0.1100.5801.000
概率(2-tailed)0.6500.4000.5800.0290.6400.003

引文著录: 张忠国, 李文欣, 吴叶枫. 血清CXCL8在进展期结直肠癌患者中的表达水平及其临床病理意义. 世界华人消化杂志 2011; 19(7): 700-704